BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoffmann P, Globig AM, Thomann AK, Grigorian M, Krisam J, Hasselblatt P, Reindl W, Gauss A. Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study. J Clin Med 2020;9:E2177. [PMID: 32664204 DOI: 10.3390/jcm9072177] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Straatmijer T, van Schaik FDM, Bodelier AGL, Visschedijk M, de Vries AC, Ponsioen CY, Pierik M, van Bodegraven AA, West RL, de Boer NKH, Srivastava N, Romkens TEH, Hoekstra J, Oldenburg B, Dijkstra G, van der Woude JC, Löwenberg M, Mujagic Z, Biemans VBC, van der Meulen‐de Jong AE, Duijvestein M. Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry. Aliment Pharmacol Ther 2022. [DOI: 10.1111/apt.17248] [Reference Citation Analysis]
2 Mishra S, Jena A, Kakadiya R, Sharma V, Ahuja V. Positioning of tofacitinib in treatment of ulcerative colitis: a global perspective. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2022.2106216] [Reference Citation Analysis]
3 Verstockt B, Volk V, Jaeckel C, Alsoud D, Sabino J, Nikolaus S, Outtier A, Krönke N, Feuerhake F, De Hertogh G, Rosenstiel P, Vermeire S, Schreiber S, Ferrante M, Aden K. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 2022;56:282-91. [PMID: 35484689 DOI: 10.1111/apt.16955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Panaccione R, Abreu MT, Lazariciu I, Mundayat R, Lawendy N, Salese L, Woolcott JC, Sands BE, Chaparro M. Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open. Aliment Pharmacol Ther 2022;55:1534-44. [PMID: 35246988 DOI: 10.1111/apt.16848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-brandt J, Cappelleri JC, Guo X, Khan N. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02215-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wang Y, Wan Z, Jin R, Xu T, Ouyang Y, Wang B, Ruan G, Bai X. Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. International Immunopharmacology 2022;105:108517. [DOI: 10.1016/j.intimp.2022.108517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ishikawa T, Kakushima N, Furukawa K, Ohno E, Kawashima H, Honda T, Ishigami M, Fujishiro M. Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis. Nagoya J Med Sci 2022;84:169-79. [PMID: 35392018 DOI: 10.18999/nagjms.84.1.169] [Reference Citation Analysis]
8 Lucaciu LA, Constantine-Cooke N, Plevris N, Siakavellas S, Derikx LAAP, Jones GR, Lees CW. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol 2021;14:17562848211064004. [PMID: 34987608 DOI: 10.1177/17562848211064004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Avni-Biron I, Bar-Gil Shitrit A, Koslowsky B, Levartovsky A, Kopylov U, Weisshof R, Aviv Cohen N, Maharshak N, Hovel D, Israeli E, Naftali T, Goren I, Snir Y, Ollech JE, Banai-Eran H, Broitman Y, Sharar-Fischler T, Dotan I, Yanai H. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Dig Liver Dis 2021:S1590-8658(21)00849-5. [PMID: 34887214 DOI: 10.1016/j.dld.2021.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2021. [PMID: 34854095 DOI: 10.1111/apt.16712] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 14.0] [Reference Citation Analysis]
11 Wiles CA, Shah NB, Bell J, Pabla BS, Scoville EA, Dalal RL, Beaulieu DB, Schwartz DA, Horst SN. Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab075] [Reference Citation Analysis]
12 Straatmijer T, van Gennep S, Duijvestein M, Ponsioen CIJ, Gecse KB, D'Haens GR, Löwenberg M. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:1288-97. [PMID: 33405424 DOI: 10.1097/MEG.0000000000002028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
13 Kozak N, Barabanchyk O, Sobchenko M, Molochek N, Dolgaia N, Penchuk Y, Mykhalchyshyn G. Application features of biological therapy in patients with autoimmune diseases. Minerva Biotechnol Biomol Res 2021;33. [DOI: 10.23736/s2724-542x.21.02762-0] [Reference Citation Analysis]
14 Lucaciu L, Constantine-cooke N, Plevris N, Siakavellas S, Derikx L, Jones G, Lees C. Real-world experience with tofacitinib in ulcerative colitis - a systematic review and meta-analysis.. [DOI: 10.1101/2021.04.27.21256170] [Reference Citation Analysis]